modelID;licenseID;project_title;project_domain;project_target;model_title;model_language;species;species_loc;dis_area;dis_loc;model_class;class_loc;choice_loc;choice_section;model_choice;species_choice;spcchc_loc;outcome_choice;outcome_loc;replace_choice;replace_sub_choice;replace_loc;reduce_choice;reduce_sub_choice;reduce_loc;refine_choice;refine_sub_choice;refine_loc;intervention_name;intervention_type;intervention_loc
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;simple accomodation and care;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;simple accomodation and care;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;simple accomodation and care;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;simple accomodation and care;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;simple accomodation and care;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;simple accomodation and care;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173905_01;20173905;In stand houden van een uniek panel van humane tumoren;Translational or applied research;human;Instandhouden;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;lack of equivalent;availability of research tools;APX_2B;disease pathology related;APX_2A;not reported;not reported;APX_2D;not reported;not reported;APX_2D;other;not reported;APX_2D;tumor implants;gene and cell-based;APX_2A
20173905_01;20173905;In stand houden van een uniek panel van humane tumoren;Translational or applied research;human;Instandhouden;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;not reported;not reported;APX_2D;not reported;not reported;APX_2D;other;not reported;APX_2D;tumor implants;gene and cell-based;APX_2A
20173905_01;20173905;In stand houden van een uniek panel van humane tumoren;Translational or applied research;human;Instandhouden;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;not reported;not reported;APX_2D;not reported;not reported;APX_2D;other;not reported;APX_2D;tumor implants;gene and cell-based;APX_2A
20173905_01;20173905;In stand houden van een uniek panel van humane tumoren;Translational or applied research;human;Instandhouden;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;lack of equivalent;availability of research tools;APX_2B;disease pathology related;APX_2A;not reported;not reported;APX_2D;not reported;not reported;APX_2D;other;not reported;APX_2D;tumor implants;gene and cell-based;APX_2A
20173905_01;20173905;In stand houden van een uniek panel van humane tumoren;Translational or applied research;human;Instandhouden;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;not reported;not reported;APX_2D;not reported;not reported;APX_2D;other;not reported;APX_2D;tumor implants;gene and cell-based;APX_2A
20173905_01;20173905;In stand houden van een uniek panel van humane tumoren;Translational or applied research;human;Instandhouden;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;not reported;not reported;APX_2D;not reported;not reported;APX_2D;other;not reported;APX_2D;tumor implants;gene and cell-based;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174266_01;20174266;Lokale radiosensitizer afgifte in combinatie met radiotherapie;Translational or applied research;human;Lokale radiosensitizer afgifte in combinatie met radiotherapie;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;temperature sensitive nanoparticle;small molecular compounds;NTS_3.1
20174286_01;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Engraftment and maintenance of RCC xenograft;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;technical feasibility;APX_2A;not applicable;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;RCC xenograft;gene and cell-based;APX_2A
20174286_01;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Engraftment and maintenance of RCC xenograft;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2A;technical feasibility;APX_2A;not applicable;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;RCC xenograft;gene and cell-based;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;social housing;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;social housing;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;social housing;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;social housing;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;drugs;small molecular compounds;APX_2A
20174286_02;20174286;Nieuwe therapie voor niercel kanker;Translational or applied research;human;Therapy of Renal Cancer;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2D;Appendix;availability of the animal model;existing model;APX_2D;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;drugs;small molecular compounds;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_01;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: subcutaneous;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_02;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: metastatic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_03;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: orthotopic;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;equipment;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174288_04;20174288;Immuun receptor therapie tegen kanker: effectief en veilig;Translational or applied research;human;Humanized mouse tumour models: safety;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;relevant information;APX_2D;not reported;not reported;APX_2D;receptors;biologics;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_01;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Beperking van trauma ten gevolge van insertie van de elektroden bundel;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundle;medical device;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_02;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;gelfoam with neurotrophic agents;biologics;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_03;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Effecten van chronishce implantatie en chronische electrische stimulatie op de neuroprotectieve werking van neurotrofe behandeling van de gehoorzenuw;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electro stimulation;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_04;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Herstel van de gehoorzenuw door middel van stamceltherapie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electron bundel;medical device;APX_2A
20174315_05;20174315;Bescherming en herstel van gehoorzenuw bij doofheid;Translational or applied research;human;Verbetering van de functionaliteit van de gehoorzenuw met een combinatie van stamcellen en elektrische stimulatie;NLD;guinea pig;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;hair-folicle-stemcells;gene and cell-based;APX_2A
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;experimental design;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174316_01;20174316;Navigatiesysteem met grotere en duidelijker beeldvorming en minder straling in de grote bloedvaten;Translational or applied research;human;Navigatiesysteem met optical shape sensing technologie in grote arterien;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;go/no-go strategy;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;use of one or both sexes;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;go/no-go strategy;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;go/no-go strategy;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;use of one or both sexes;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;go/no-go strategy;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;go/no-go strategy;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;use of one or both sexes;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;go/no-go strategy;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;go/no-go strategy;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;use of one or both sexes;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174387_01;20174387;Sensorische gevoeligheid en behandeling voor verslaving;Translational or applied research;human;Effects of social environment on drug self-administration behaviour in high and low SPS rats;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;go/no-go strategy;APX_2D;other;not reported;APX_2D;cocaine;small molecular compounds;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_01;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Pilot - Behavioural assays of agression and attention;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;behaviour;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_02;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;two-phonon imaging;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_03;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Electrophysiology during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Spontaneous;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrophysiology and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174424_04;20174424;Onderzoek naar controle van emoties en cognitie bij ADHD en antisociale gedragsstoornis;Translational or applied research;human;Optogenetics and two-photon imaging during behaviour;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;optogenetic, two-photon and behaviour;diagnostic tool;APX_2A
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174426_01;20174426;Preventie en behandeling met werkzame stoffen in kruiden en gezondheid bevorderende bacteri<eb>n in muismodellen voor allergische astma;Translational or applied research;human;"Huisstofmijt geinduceed model voor allergische astma (acuut, chronisch en corticosteroid-resistent); invloed van werkzame stoffen in kruiden en probiotica";NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;herbal extracts;herbal products;NTS_3.1
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_01;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Spondylodiscitis model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_02;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;XXXX model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bioluminescent S.aureus;gene and cell-based;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_03;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Implant Infection model in rats;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20174465_04;20174465;Biofilm specifieke diagnostiek en behandeling van orthopedische infecties;Translational or applied research;human;Subcutaneous implant infection rat model;ENG;rat;NTS_3.3;Infectious disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of readout;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;undisclosed;undisclosed;APX_2A
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_01;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Long-term developmental effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - safety and efficacy studies;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184568_02;20184568;Effecten van dieet op de ontwikkeling van de hersenen en het immuunsysteem in de context van ontsteking die optreedt tijdens de zwangerschap;Translational or applied research;human;Direct effects of metarnal dietary intervention in a murine model of LPS-induced intruterine inflammation - an investigative study;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;foodsupplements;small molecular compounds;NTS_3.1
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;expertise;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184624_01;20184624;De ontwikkeling van een muismodel voor onderzoek naar hersenbloedingen;Translational or applied research;human;Experiment;ENG;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;S1000A8/A9 protein;biologics;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;existing model;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;availability of GMOs;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_01;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Breeding and maintenance of genetically altered animals;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;not reported;APX_2A;not reported;not reported;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;breeding Cre-LoxP genetic deletion;gene and cell-based;APX_2A
20184627_02;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;SSc-like mice models;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;dose finding;diagnostic tool;APX_2A
20184627_02;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;SSc-like mice models;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;dose finding;diagnostic tool;APX_2A
20184627_02;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;SSc-like mice models;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;dose finding;diagnostic tool;APX_2A
20184627_02;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;SSc-like mice models;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;dose finding;diagnostic tool;APX_2A
20184627_02;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;SSc-like mice models;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;dose finding;diagnostic tool;APX_2A
20184627_02;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;SSc-like mice models;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;dose finding;diagnostic tool;APX_2A
20184627_02;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;SSc-like mice models;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;dose finding;diagnostic tool;APX_2A
20184627_02;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;SSc-like mice models;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;dose finding;diagnostic tool;APX_2A
20184627_02;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;SSc-like mice models;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;dose finding;diagnostic tool;APX_2A
20184627_02;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;SSc-like mice models;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;dose finding;diagnostic tool;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184627_03;20184627;Mechanismen en vernieuwde behandelingen in systemische sclerosis;Translational or applied research;human;Immune cells modification;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;cell deletion, humanized mice;gene and cell-based;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184645_01;20184645;Nieuwe behandelingmethoden van kapotte vaatkleppen in de benen;Translational or applied research;human;Nieuwe behandeling van Chronisch Diepe Veneuze Klep Insufficiency (CDVI);NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;artificial valve;medical device;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_01;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Generation of novel genetically modified mice and maintenance of colonies of genetically modified mice, including breeding with discomfort;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;generation fof GMO mice lines;gene and cell-based;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;infrastructure;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;close genetic homology;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;close genetic/protein homology;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;simple accomodation and care;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_02;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Elucidation of molecular mechanisms underlying pathogenesis of temporal lobe epilepsy;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.4.1;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bioassays;diagnostic tool;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;infrastructure;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;literature review;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184646_03;20184646;Identificatie en karakteristiek van ziekteprocessen die ten grondslag liggen aan Temporaalkwabepilepsie;Translational or applied research;human;Functional evaluation of the molecular mechanisms in epileptogenesis;ENG;mouse;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;phenotype knockdown;gene and cell-based;APX_2A
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_01;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal cigarette smoke exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_02;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Maternal vehicle/industrial emission exposure;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar ethiology;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;similar disease pathology or symptoms;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_03;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Vaccination model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar organ system;availability of research tools;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;small molecular compounds;NTS_3.1
20184724_04;20184724;Effecten van blootstelling aan luchtverontreinigende deeltjes (fijnstof en sigarettenrook) op drachtige muizen en hun nakomelingen;Translational or applied research;human;Allergy model offspring;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;pre-probiotics;biologics;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;regulatory requirement EMA or FDA;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184784_01;20184784;Onderzoek naar de veiligheid en toepasbaarheid van nieuw spinaal sealant;Translational or applied research;human;Testen van nieuw spinaal sealant in varkens;NLD;pig;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2A;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;reduction of discomfort;equipment;APX_2D;sealant;medical device;NTS_3.1
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184785_01;20184785;De darm-spier-brein as in COPD: de effecten van dieetinterventie op extra-pulmonaire problemen;Translational or applied research;human;The effects of a dietary intervention on extra-pulmonary symptoms in COPD exacerbation models;ENG;mouse;NTS_3.3;Respiratory disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;nutritional concept;undisclosed;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_01;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI of microvascular reperfusion and lesion development in multiple animal models of stroke with different degrees of recanalization;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_02;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;MRI, ultrasound and laser speckle flowmetry in an intraluminal filament model of stroke and in an embolic clot model;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI and ultrasound;diagnostic tool;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20184985_03;20184985;Onvolledige doorbloeding van het brein na een acuut herseninfarct;Translational or applied research;human;Testing a novel therapeutic intervention for improved reperfusin and tissue salvage after stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;trombolytic;small molecular compounds;APX_2A
20185005_01;20185005;De relatie tussen hersenactiviteit en MRI signalen;Translational or applied research;human;Functional MRI, Optical Imaging and Electrophysiological recordings in rat brain during somatosensory stimulation;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;(bio)marker identification;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;NTS_3.1
20185005_01;20185005;De relatie tussen hersenactiviteit en MRI signalen;Translational or applied research;human;Functional MRI, Optical Imaging and Electrophysiological recordings in rat brain during somatosensory stimulation;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;(bio)marker identification;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;NTS_3.1
20185005_01;20185005;De relatie tussen hersenactiviteit en MRI signalen;Translational or applied research;human;Functional MRI, Optical Imaging and Electrophysiological recordings in rat brain during somatosensory stimulation;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;(bio)marker identification;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;NTS_3.1
20185005_01;20185005;De relatie tussen hersenactiviteit en MRI signalen;Translational or applied research;human;Functional MRI, Optical Imaging and Electrophysiological recordings in rat brain during somatosensory stimulation;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;(bio)marker identification;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;NTS_3.1
20185005_01;20185005;De relatie tussen hersenactiviteit en MRI signalen;Translational or applied research;human;Functional MRI, Optical Imaging and Electrophysiological recordings in rat brain during somatosensory stimulation;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;(bio)marker identification;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;NTS_3.1
20185005_01;20185005;De relatie tussen hersenactiviteit en MRI signalen;Translational or applied research;human;Functional MRI, Optical Imaging and Electrophysiological recordings in rat brain during somatosensory stimulation;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;(bio)marker identification;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;MRI;diagnostic tool;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar organ system;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185105_01;20185105;Minimaal invasieve laser geassisteerde bypass techniek;Translational or applied research;human;Coronaire bypass chirurgie gebaseerd op de ELANA techniek;NLD;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;lasertechnique;medical device;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_01;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Feasibility, adverse effects, biocompatibility and retention studies in healthy animals;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_02;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;High fat groov moded;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;accomodation and care;cage enrichment;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;prior studies;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;intervention related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;diagnostic tool;NTS_3.1
20185184_03;20185184;Het gebruik van lama antilichamen bij artrose;Translational or applied research;human;Destabilization of the medial meniscus model;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;PPL_3.4.2;no alternative model;kinetics or biodistribution;APX_2D;experimental design;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;lama antibodies;biologics;NTS_3.1
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_01;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Isolation of satellite cells;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;isolation of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185364_02;20185364;Verbetering van de functie van het zachte gehemelte bij schisispatienten door middel van tissue engeneering;Translational or applied research;human;Surgical implantation of electrodes and transmitters and surgical wounding in the the soft palate;ENG;rat;NTS_3.3;Other disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;implant of satelite cells;gene and cell-based;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_01;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Testosteron loaded microsphere dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;testosteron microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;reported as fact;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185824_02;20185824;Plaatselijke afgifte van geneesmiddelen in de knieholte voor het herstel van botschade tijdens artrose;Translational or applied research;human;Alandronate dose finding study in na<ef>ve rat knee joints;ENG;rat;NTS_3.3;Immune disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;alendronate microspheres;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;infrastructure;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20185825_01;20185825;Evaluatie van de combinatie van alendronaat en testosteron in gestandaardiseerde defecten in de kaak van mini-pigs;Translational or applied research;human;Evaluation of a combination of alendronate and testosteron in standardized bone defects in mini-pigs;ENG;pig;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in vivo (pilot) studies;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;alendronate and testosteron;small molecular compounds;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_01;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo characterization of the nanoparticles for biodistribution, dosimetry, dosing and acquisition protocols in healthy mice and disease models;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;nanoparticles, particles;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186044_02;20186044;Nanodeeltjes voor mutimodale beeldvorming van specifieke immuncel populatie;Translational or applied research;human;In vivo monitoring responses to immune therapeutic interventions;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;availability of research tools;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;labeled cells;diagnostic tool;APX_2A
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_01;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Karakterisering van het expressieprofiel van Lgr-receptoren en de bijbehorende R-spondine-liganden gedurende de ontwikkeling van de cochlea van de muis;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;prior studies;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186105_02;20186105;Mogelijk herstel van gehoor bij doofheid door groei van zintuigcellen te stimuleren;Translational or applied research;human;Veranderingin expressie van Lgr-receptoren en de bijbehorende R-spondine-liganden na inductie van haarceldegeneratie en mogelijke regeneratie met exogene groeifactoren;NLD;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;specific proteins;diagnostic tool;NTS_3.1
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_01;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Breeding of homozygous DMSXL mice;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;breeding of DMSXL mice;gene and cell-based;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_02;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the biodistribution of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;diagnostic tool;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_03;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the short-term efficacy of new formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186204_04;20186204;Identificatie van formuleringen om de biodistributie en effectiviteit van antisense oligonucleotide medicijnen te verbeteren voor myotone dystrofie type 1;Translational or applied research;human;Determining the long-term efficacy of neuw formulations;ENG;mouse;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;expertise;APX_2D;formulations;small molecular compounds;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_01;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Proof of principle;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_02;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in rat;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_03;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Long-term and safety;NLD;rat;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar anatomy;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar anatomy;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar anatomy;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar anatomy;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;sealant;medical device;APX_2A
20186324_04;20186324;Gel ter voorkoming van lekkage van darmnaden;Translational or applied research;human;Efficacy in pig;NLD;pig;APX_2B;Gastrointestinal disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prior studies;not reported;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;sealant;medical device;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186325_01;20186325;Voorkomen van infecties veroorzaakt door niet typeerbare Haemophilus influenzae door vaccinatie;Translational or applied research;human;IAV-H influenza co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;expertise;APX_2D;vacines;vaccines;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_01;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Generation and monitoring of genetically modified zebrafish lines;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;breeding GMO zebrafish line;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;close genetic homology;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;similar anatomy;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;existing model;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;cost effectiveness;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;anti-epileptic drugs;small molecular compounds;APX_2A
20186347_02;20186347;Gerichte epilepsietherapie getest in zebravissen;Translational or applied research;human;Investigating efficacy of anti-epileptic therapeutic treatments of zebrafish brain;ENG;zebrafish;NTS_3.3;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;gene therapy;gene and cell-based;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_01;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation pilot;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_02;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep ectopic implantation model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;experimental design;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;sensitivity;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_03;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Rabbit implantation/injection model;ENG;rabbit;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;availability of research tools;PPL_3.4.1;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_04;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep iliac wing defect model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of research tools;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;experimental design;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar organ system;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;prefered to other model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186348_05;20186348;De effectiviteit van nieuwe botvervangers in diermodellen;Translational or applied research;human;Sheep spinal fusion model;ENG;sheep;APX_2B;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;experimental design;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;literature review;build on existing literature;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186349_01;20186349;Geheugen en stress als voorspellers voor posttraumatische stressstoornis;Translational or applied research;human;Behavioral experiments in male rats: predictive value of memory XXXX for PTSD susceptibility;ENG;rat;NTS_3.3;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;best reagents and protocols;APX_2D;social stress and trauma;diagnostic tool;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;regulatory requirement EMA or FDA;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;prefered to other model;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of research tools;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;experimental design;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186504_01;20186504;Toxicologie en farmacologie van stoffen die kankergroei en metastasering remmen door uitschakeling van de groeihormoonreceptor;Translational or applied research;human;Honden: Farmacokinetiek en chronische toxiciteit;NLD;dog;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.3;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.3;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;prior (pilot) studies;APX_2D;cytostatic drug;small molecular compounds;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;close genetic homology;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20186505_01;20186505;Wat is de ziekmakende stof bij auto-immuuntrombose?;Translational or applied research;human;FeCl3-geinduceerde vasculaire occlusie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;availability of the animal model;availability of GMOs;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;biologicals;biologics;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of regulatory guidelines;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar biodistribution;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197225_01;20187225;Een biologisch afbreekbare gel die langdurig lokale verdoving afgeeft bij operaties aan het bot;Translational or applied research;human;Proof of Concept: a biodegradable local anesthetic delivery device for use in instrumented skeletal surgery;ENG;rat;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;equipment;APX_2D;biodegradable delivery system;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197424_01;20197424;Behandelen van middenoorinfecties door nieuwe antibiotica;Translational or applied research;human;IAV-NTHi co-infection model;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;lowest possible species;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;antibiotics;small molecular compounds;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_01;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Xenograft tumor model using tumor cell lines;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_02;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized tumor model using patient derived tumor cells;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_03;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized model: safety and bio-distribution model;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_03;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized model: safety and bio-distribution model;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_03;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized model: safety and bio-distribution model;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_03;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized model: safety and bio-distribution model;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_03;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized model: safety and bio-distribution model;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_03;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized model: safety and bio-distribution model;ENG;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_03;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized model: safety and bio-distribution model;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_03;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized model: safety and bio-distribution model;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_03;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized model: safety and bio-distribution model;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_03;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized model: safety and bio-distribution model;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_03;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized model: safety and bio-distribution model;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197467_03;20197467;Modificeren van navelstrengbloed naar therapien om kanker te behandelen;Translational or applied research;human;Humanized model: safety and bio-distribution model;ENG;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;immunotherapy product;gene and cell-based;APX_2A
20197585_01;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Breeding;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding of PINK1 KO rats;gene and cell-based;APX_2A
20197585_01;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Breeding;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding of PINK1 KO rats;gene and cell-based;APX_2A
20197585_01;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Breeding;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding of PINK1 KO rats;gene and cell-based;APX_2A
20197585_01;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Breeding;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding of PINK1 KO rats;gene and cell-based;APX_2A
20197585_01;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Breeding;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding of PINK1 KO rats;gene and cell-based;APX_2A
20197585_01;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Breeding;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding of PINK1 KO rats;gene and cell-based;APX_2A
20197585_01;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Breeding;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding of PINK1 KO rats;gene and cell-based;APX_2A
20197585_01;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Breeding;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding of PINK1 KO rats;gene and cell-based;APX_2A
20197585_01;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Breeding;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding of PINK1 KO rats;gene and cell-based;APX_2A
20197585_01;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Breeding;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding of PINK1 KO rats;gene and cell-based;APX_2A
20197585_01;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Breeding;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding of PINK1 KO rats;gene and cell-based;APX_2A
20197585_01;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Breeding;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;duration of the study;APX_2D;breeding of PINK1 KO rats;gene and cell-based;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar organ system;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar organ system;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar ethiology;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar ethiology;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;prior studies;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;prior studies;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar organ system;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar organ system;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar ethiology;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar ethiology;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;prior studies;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;prior studies;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02a;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar organ system;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar organ system;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar ethiology;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar ethiology;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;prior studies;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.2;Main Text;prior studies;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar organ system;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar organ system;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar ethiology;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;similar ethiology;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;prior studies;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.2;Main Text;prior studies;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_02b;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Pharmacokinetic studies;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;reduction of discomfort;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;prior studies;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_03;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in PINK1 KO rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Genetically modified;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;MRI, SPECT;diagnostic tool;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_04;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in 6-OHDA induced PD rat model;ENG;rat;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar organ system;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar ethiology;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;prior studies;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197585_05;20197585;Het vinden van effectieve behandelingen voor metabole ziekten;Translational or applied research;human;Treatment efficacy studies in MPTP induced PD mouse model;ENG;mouse;APX_2B;Nervous and mental disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;strategy;go/no-go strategy;APX_2D;reduction of discomfort;expertise;APX_2D;ROS-redox modulators;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of research tools;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;availability of expertise;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;availability of expertise;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;expertise;APX_2D;available drugs;small molecular compounds;APX_2A
20197987_01;20197987;Therapeutische behandeling van chronische nierziekte;Translational or applied research;human;Farmacologische interventie;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;available drugs;small molecular compounds;APX_2A
20198024_01;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;FeCl3-geinduceerde trombose in de arteria carotis in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_01;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;FeCl3-geinduceerde trombose in de arteria carotis in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_01;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;FeCl3-geinduceerde trombose in de arteria carotis in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_01;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;FeCl3-geinduceerde trombose in de arteria carotis in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_01;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;FeCl3-geinduceerde trombose in de arteria carotis in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_01;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;FeCl3-geinduceerde trombose in de arteria carotis in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_01;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;FeCl3-geinduceerde trombose in de arteria carotis in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_01;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;FeCl3-geinduceerde trombose in de arteria carotis in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_01;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;FeCl3-geinduceerde trombose in de arteria carotis in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_01;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;FeCl3-geinduceerde trombose in de arteria carotis in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_02;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Atherosclerose door LDLr knock-out in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease specific guideline;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;close genetic/protein homology;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;close genetic/protein homology;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_03;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Corticale beroerte door emboliserende trombus (MCAO) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;close genetic/protein homology;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_1.3;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198024_04;20198024;Het verbeteren van de diagnose en behandeling van vaatziekten met behulp van antilichamen;Translational or applied research;human;Microvascularie trombose door Trombotische Thrombocytopenische Purpura (TTP) in muizen;NLD;mouse;NTS_3.3;Cardiovascular disorders;NTS_3.1;Genetically modified and induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;antibodies against signaling molecules;biologics;APX_2A
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;reported as fact;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of expertise;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;essential treatments groups;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1
20198365_01;20198365;Preventie van voedselallergie door middel van duurzame omega-3 algenolie;Translational or applied research;human;Allergie preventie met duurzame omega-3 algenolie in muismodellen voor voedselallergie;NLD;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;strategy;go/no-go strategy;APX_2D;methods used in procedures;expertise;APX_2D;plant based oils;herbal products;NTS_3.1